ReCode Therapeutics
CA - Menlo Park
Biotechnology1 H-1B visas (FY2023)Focus: Nucleic Acid Therapeutic Delivery
ReCode Therapeutics is a life sciences company focused on Nucleic Acid Therapeutic Delivery.
Rare DiseasesMetabolic Diseases
Funding Stage
PUBLIC
Open Jobs
1
Pipeline & Clinical Trials
Spirometry
Primary Ciliary DyskinesiaClinical Trials (1)
NCT05685186A Longitudinal, Observational Study of Primary Ciliary Dyskinesia in Adults
N/ASano Genetics Testing Kit
Primary Ciliary DyskinesiaClinical Trials (1)
NCT06172374A Study Providing Genetic Testing to Find Those Who May Have Primary Ciliary Dyskinesia for Potential Clinical Trials
N/ARCT1100
Primary Ciliary DyskinesiaClinical Trials (1)
NCT06600425A Study to Assess the Safety, Tolerability, Ciliary Rescue, and Pharmacodynamics of RCT1100 in Adults With PCD
Phase 1Phase 1
Clinical Trials (1)
NCT06633757Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance
Phase 1RCT1100
Primary Ciliary DyskinesiaClinical Trials (1)
NCT05737485Study Evaluating the Safety and Tolerability of RCT1100 in Healthy and PCD Subjects
Phase 1RCT2100
Cystic FibrosisClinical Trials (1)
NCT06237335A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF
Phase 2Open Jobs (1)
Interview Prep Quick Facts
Founded: 2010
Portfolio: 6 clinical trials
H-1B (2023): 1 approval
Open Roles: 1 active job
Hiring Trend
Stable
1
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles
Visa Sponsorship
Sponsors Work Visas
H-1B Petitions (FY2023)
1
Approved
0
Denied
100%
Rate
Source: USCIS H-1B Employer Data Hub